“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...
The intellectual property was originally developed through a collaboration of Shuttle Pharma scientists with investigators from Georgetown University. The ...
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was ...
Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatm...
Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...
Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mut...
Trial expected to screen more than 1900 early-stage breast cancer patients at 120+ sites in 12 countries across Europe, commencing in...
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfo...
American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study r...
To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targete...
Charles River Laboratories International, Inc. announced the ability to conduct preclinical cancer research using ITCC-P4’s well-characterized collec...
In conjunction with breast cancer awareness month, the Malaysia Healthcare Travel Council (MHTC) together with Subang Jaya Medical Centre, organised a thou...
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) fo...
© 2024 Biopharma Boardroom. All Rights Reserved.
